Join us for the next RMIP Research Spotlight featuring Dr. Christopher Breuer of Nationwide Children’s Hospital.
Register Today for the event on Wednesday, September 9th at 1:00-2:00 PM ET.
Dr. Christopher Breuer is a Professor of Surgery and Director of Tissue Engineering at Ohio State University and Director of the Center for Regenerative Medicine and Endowed Chair of Surgical Research at Nationwide Children’s Hospital. Dr. Breuer’s research focuses on understanding neotissue formation to design next-generation grafts and heart valves that reduce reoperations and long-term complications. His work is reshaping surgical options in pediatric heart care and advancing regenerative solutions for complex congenital cardiac defects.
Presentation Abstract: Children with single-ventricle congenital heart disease currently receive synthetic Fontan conduits that cannot grow and are prone to thrombosis and stenosis, leading to repeat interventions and long-term complications. Tissue engineered vascular grafts (TEVGs) using bone marrow–seeded biodegradable scaffolds have shown that these conduits can remodel into living, growing neovessels, with a characteristic phase of early narrowing followed by spontaneous reverse remodeling. This clinical research integrates computational modeling and mechanobiology to define the drivers of neotissue formation and stenosis and to optimize second-generation TEVGs, which are being tested as extracardiac Fontan conduits in an ongoing clinical trial.
Jeran Stratford
Join us for the next RMIP Research Spotlight featuring Dr. Christopher Breuer of Nationwide Children’s Hospital.
Register Today for the event on Wednesday, September 9th at 1:00-2:00 PM ET.
Dr. Christopher Breuer is a Professor of Surgery and Director of Tissue Engineering at Ohio State University and Director of the Center for Regenerative Medicine and Endowed Chair of Surgical Research at Nationwide Children’s Hospital. Dr. Breuer’s research focuses on understanding neotissue formation to design next-generation grafts and heart valves that reduce reoperations and long-term complications. His work is reshaping surgical options in pediatric heart care and advancing regenerative solutions for complex congenital cardiac defects.
Presentation Abstract: Children with single-ventricle congenital heart disease currently receive synthetic Fontan conduits that cannot grow and are prone to thrombosis and stenosis, leading to repeat interventions and long-term complications. Tissue engineered vascular grafts (TEVGs) using bone marrow–seeded biodegradable scaffolds have shown that these conduits can remodel into living, growing neovessels, with a characteristic phase of early narrowing followed by spontaneous reverse remodeling. This clinical research integrates computational modeling and mechanobiology to define the drivers of neotissue formation and stenosis and to optimize second-generation TEVGs, which are being tested as extracardiac Fontan conduits in an ongoing clinical trial.